Context Multiple sclerosis (MS) is a chronic progressive neurological disease common in young adults.1 Canada has one of the highest prevalence rates of MS in the world.2 MS causes significant disability due to mobility and vision problems, fatigue, incontinence, and cognitive impairment.1 The Public Health Agency of Canada estimated that the total costs associated with MS in 2000-2001 for hospitalization, treatment, and lost productivity due to morbidity and premature mortality were $950.5 million.1 Treatments involve suppressing or modifying the immune response, but there is currently no cure for MS................

..............................Objectives
The purpose of this report is to review recent developments in the investigation of CCSVI for the treatment of MS. This report will update information presented in a previous Environmental Scan, released in December 2010.18 The following questions will be addressed: Which clinical trials in North America are currently studying the association of CCSVI with MS? What is the status of funding for CCSVI research in Canada? What other initiatives are taking place in Canada with regard to CCSVI?

For full report go to: http://www.cadth.ca/media/pdf/MS_Liberation_Update_es-20_e.pdf